NEW YORK, July 19, 2018 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ:ESTA) today announced that the company’s common stock commenced trading on the Nasdaq Stock Market under the trading symbol “ESTA” following its initial public offering. Establishment Labs is a global medical technology company focused on breast aesthetics and reconstruction technologies.
Founder and Chief Executive Officer Juan José Chacón-Quirós, joined by members of the company’s management team and family, celebrated the company’s first day of trading by visiting the exchange.
“Today’s listing on Nasdaq represents a significant milestone for Establishment Labs and our shareholders,” said Mr. Chacón-Quirós. “It’s an honor to be the first company headquartered in Costa Rica to be listed on a major stock exchange in the United States.”
“We welcome Establishment Labs to the Nasdaq family, and look forward to supporting their continued success,” said Joe Brantuk, Vice President of Nasdaq. “Establishment Labs continuously works to improve patient safety and aesthetic outcomes while simultaneously working towards its entry into the U.S. market.”
About Establishment Labs
Establishment Labs (NASDAQ:ESTA) is a global medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at two FDA compliant state-of-the-art facilities in Costa Rica and currently sold in over 60 countries through exclusive distributors or a direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA to initiate the Motiva Implant® clinical trial in the United States. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes Divina® 3D Simulation System, Puregraft, and MotivaImage® Centers.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0d6af859-9e48-4743-b696-4f18a4b1befa